Coherus Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	21.83	42.17	26.39	257.24	211.04	326.55
Revenue Growth (YoY)	33.50%	59.81%	-89.74%	21.89%	-35.37%	-31.37%
Cost of Revenue	7.12	13.81	8.73	158.99	70.08	57.59
Gross Profit	14.71	28.36	17.66	98.25	140.96	268.96
Selling, General & Admin	97.68	100.6	125.48	192.02	198.48	169.71
Research & Development	106.08	108.89	91.83	109.44	199.36	363.11
Total Operating Expenses	203.76	209.49	217.32	301.45	397.84	532.82
Operating Income	-82.03	-181.13	-199.65	-203.2	-256.88	-263.86
Interest Expense	-9.04	-9	-10.73	-40.54	-32.47	-22.96
Other Non-Operating Income (Expense)	8.23	7.01	-5.01	5.47	-2.4	-0.28
Total Non-Operating Income (Expense)	-0.81	-1.99	-15.74	-35.07	-34.87	-23.24
Pretax Income	-172.66	-183.12	-215.39	-238.27	-291.75	-287.1
Provision for Income Taxes	-	-	-	-0.38	-	-
Net Income	545.19	519.17	272.41	-237.89	-291.75	-287.1
Earnings From Discontinued Operations	358.93	351.15	243.9	-	-	-
Net Income to Common	545.19	519.17	272.41	-237.89	-291.75	-287.1
Net Income Growth	-	90.59%	-	-	-	-
Shares Outstanding (Basic)	122	117	115	94	78	75
Shares Outstanding (Diluted)	122	117	115	94	78	75
Shares Change (YoY)	6.02%	2.26%	21.66%	21.30%	2.89%	-9.63%
EPS (Basic)	-1.29	1.43	0.25	-2.53	-3.76	-3.81
EPS (Diluted)	-1.29	1.43	0.25	-2.53	-3.76	-3.81
EPS Growth	-	472.00%	-	-	-	-
Shares Outstanding	154.22	121.16	115.62	112.22	77.78	76.93
Free Cash Flow	-170.57	-138.51	-20.44	-174.88	-241.12	-38.72
Free Cash Flow Per Share	-1.40	-1.18	-0.18	-1.86	-3.11	-0.51
Gross Margin	67.40%	67.24%	66.93%	38.19%	66.79%	82.36%
Operating Margin	-375.86%	-429.51%	-756.58%	-78.99%	-121.72%	-80.80%
Profit Margin	853.45%	398.43%	108.03%	-92.48%	-138.25%	-87.92%
FCF Margin	-781.55%	-328.45%	-77.46%	-67.98%	-114.25%	-11.86%
EBITDA	-78.27	-177.21	-194.38	-199.41	-253.18	-260.4
EBITDA Margin	-358.63%	-420.21%	-736.58%	-77.52%	-119.97%	-79.74%
EBIT	-82.03	-181.13	-199.65	-203.2	-256.88	-263.86
EBIT Margin	-375.86%	-429.51%	-756.58%	-78.99%	-121.72%	-80.80%
Effective Tax Rate	-	0.00%	0.00%	0.16%	0.00%	0.00%

SEC Filings: 10-K · 10-Q